Prolonged Administration Enhances the Renoprotective Effect of Pentoxifylline via Anti-Inflammatory Activity in Streptozotocin-Induced Diabetic Nephropathy

被引:21
作者
Han, Kum Hyun [1 ]
Han, Sang Youb [1 ]
Kim, Han Seong [2 ]
Kang, Young Sun [3 ]
Cha, Dae Ryong [3 ]
机构
[1] Inje Univ, Ilsan Paik Hosp, Dept Internal Med, Coll Med, Goyang 411706, Gyeonggi Prov, South Korea
[2] Inje Univ, Ilsan Paik Hosp, Dept Pathol, Coll Med, Goyang 411706, Gyeonggi Prov, South Korea
[3] Korea Univ, Dept Internal Med, Coll Med, Ansan Hosp, Ansan, South Korea
关键词
diabetic nephropathy; inflammation; pentoxifylline; MONOCYTE CHEMOATTRACTANT PROTEIN-1; CONVERTING ENZYME-INHIBITION; TUMOR-NECROSIS-FACTOR; GENE-THERAPY; SHORT-TERM; URINARY; PROGRESSION; EXPRESSION; EXCRETION; BLOCKADE;
D O I
10.1007/s10753-009-9167-6
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The beneficial effects of pentoxifylline (PTX), which has an anti-inflammatory and renoprotective effect in diabetic nephropathy, are not completely understood. This study investigates whether prolonged administration of PTX (40 mg/kg, per oral) is effective in streptozotocin-induced diabetic nephropathy. The amount of urinary protein was higher in the diabetic rats than in the control rats. The amount remained unchanged after 4 weeks and decreased after 8 weeks of PTX treatment. Accumulation of monocyte chemoattractant peptide-1 (MCP-1) and mouse monoclonal anti-monocyte/macrophage antibody (ED-1) positive cells was higher in untreated diabetic rats than in the control rats. PTX administration ameliorated the urinary MCP-1 excretion and interstitial infiltration of ED-1 positive cells at 4 weeks. Further, in diabetic rats, administration of PTX for 4 weeks inhibited the renal inflammatory reaction, and when administration for 8 weeks, it prevented proteinuria. These findings support the hypothesis that prolonged administration enhances the protective effects of PTX.
引用
收藏
页码:137 / 143
页数:7
相关论文
共 31 条
[1]   Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy [J].
Banba, N ;
Nakamura, T ;
Matsumura, M ;
Kuroda, H ;
Hattori, Y ;
Kasai, K .
KIDNEY INTERNATIONAL, 2000, 58 (02) :684-690
[2]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[3]   Progression to overt nephropathy in type 2 diabetes - The Casale Monferrato study [J].
Bruno, G ;
Merletti, F ;
Biggeri, A ;
Bargero, G ;
Ferrero, S ;
Pagano, G ;
Perin, PC .
DIABETES CARE, 2003, 26 (07) :2150-2155
[4]   Pentoxifylline suppresses renal tumour necrosis factor-α and ameliorates experimental crescentic glomerulonephritis in rats [J].
Chen, YM ;
Ng, YY ;
Lin, SL ;
Chiang, WC ;
Lan, HY ;
Tsai, TJ .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (05) :1106-1115
[5]   Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases [J].
Chen, YM ;
Lin, SL ;
Chiang, WC ;
Wu, DK ;
Tsai, TJ .
KIDNEY INTERNATIONAL, 2006, 69 (08) :1410-1415
[6]   Macrophages in mouse type 2 diabetic nephropathy: Correlation with diabetic state and progressive renal injury [J].
Chow, F ;
Ozols, E ;
Nikolic-Paterson, DJ ;
Atkins, RC ;
Tesch, GH .
KIDNEY INTERNATIONAL, 2004, 65 (01) :116-128
[7]   Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects:: The Insulin Resistance Atherosclerosis Study [J].
Festa, A ;
D'Agostino, R ;
Howard, G ;
Mykkänen, L ;
Tracy, RP ;
Haffner, SM .
KIDNEY INTERNATIONAL, 2000, 58 (04) :1703-1710
[8]   Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats [J].
Han, Sang-Youb ;
Kim, Cy-Hyun ;
Kim, Han-Seong ;
Jee, Yi-Hwa ;
Song, Hye-Kyoung ;
Lee, Mi-Hwa ;
Han, Kum-Hyun ;
Kim, Hyoung-Kyu ;
Kang, Young-Sun ;
Han, Jee-Young ;
Kim, Young-Sik ;
Cha, Dae-Ryong .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (05) :1362-1372
[9]   Effect of retinoic acid in experimental diabetic nephropathy [J].
Han, SY ;
So, GA ;
Jee, YH ;
Han, KH ;
Kang, YS ;
Kim, HK ;
Kang, SW ;
Han, DS ;
Han, JY ;
Cha, DR .
IMMUNOLOGY AND CELL BIOLOGY, 2004, 82 (06) :568-576
[10]   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].
Lewis, EJ ;
Hunsicker, LG ;
Clarke, WR ;
Berl, T ;
Pohl, MA ;
Lewis, JB ;
Ritz, E ;
Atkins, RC ;
Rohde, R ;
Raz, I .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860